A detailed history of International Assets Investment Management, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, International Assets Investment Management, LLC holds 113,863 shares of EDIT stock, worth $362,084. This represents 0.09% of its overall portfolio holdings.

Number of Shares
113,863
Previous 31,457 261.96%
Holding current value
$362,084
Previous $147 Million 77.27%
% of portfolio
0.09%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

BUY
$3.39 - $5.96 $279,356 - $491,139
82,406 Added 261.96%
113,863 $33.4 Million
Q2 2024

Jul 30, 2024

BUY
$4.67 - $7.28 $14,010 - $21,840
3,000 Added 10.54%
31,457 $147 Million
Q4 2023

Jan 25, 2024

SELL
$6.25 - $11.11 $1.62 Million - $2.89 Million
-259,812 Reduced 90.13%
28,457 $288,000
Q4 2023

Jan 24, 2024

BUY
$6.25 - $11.11 $1.66 Million - $2.95 Million
265,812 Added 1183.65%
288,269 $28.5 Million
Q3 2023

Oct 04, 2023

BUY
$6.92 - $9.31 $63,664 - $85,652
9,200 Added 69.4%
22,457 $175,000
Q2 2023

Jul 20, 2023

BUY
$6.36 - $11.47 $84,314 - $152,057
13,257 New
13,257 $109,000
Q1 2022

May 03, 2022

SELL
$14.08 - $27.63 $149,839 - $294,038
-10,642 Closed
0 $0
Q4 2021

Jan 21, 2022

BUY
$26.55 - $40.57 $108,191 - $165,322
4,075 Added 62.05%
10,642 $283,000
Q3 2021

Oct 28, 2021

SELL
$39.27 - $72.94 $37,031 - $68,782
-943 Reduced 12.56%
6,567 $270,000
Q2 2021

Jul 14, 2021

BUY
$31.29 - $56.64 $229,981 - $416,304
7,350 Added 4593.75%
7,510 $425,000
Q4 2020

Jan 22, 2021

BUY
$27.07 - $84.35 $4,331 - $13,496
160 New
160 $11.2 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $219M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track International Assets Investment Management, LLC Portfolio

Follow International Assets Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of International Assets Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on International Assets Investment Management, LLC with notifications on news.